2022
DOI: 10.1093/jacamr/dlac040
|View full text |Cite
|
Sign up to set email alerts
|

Clinical challenges treatingStenotrophomonas maltophiliainfections: an update

Abstract: Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes treating infections caused by S. maltophilia a great clinical challenge. Clinical management is further complicated by its molecular heterogeneity that is reflected in the uneven distribution of antibiotic resistance and virulence determinants among different strains, the shortcomings of available antimicrobial susceptibility tests and the l… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
46
0
5

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 72 publications
(84 citation statements)
references
References 265 publications
0
46
0
5
Order By: Relevance
“…S. maltophilia is characterized by high resistance to antibiotics, including broad-spectrum β-lactam, aminoglycosides and carbapenem, which is associated with high morbidity and mortality in immunocompromised patients ( 2 , 3 ). Important to mention here that previous therapy with broad-range antibiotics, especially carbapenem has been deemed as a risk factor for S. maltophilia infection ( 4 , 5 ). The attributed mortality rates of S. maltophilia infections in pneumonia range between 25 and 75%, 26 and 28% in case of nosocomial bloodstream infections, and crude mortality rates of S. maltophilia bacteremia range from 21 to 69% ( 6 , 7 ).…”
Section: Introductionmentioning
confidence: 99%
“…S. maltophilia is characterized by high resistance to antibiotics, including broad-spectrum β-lactam, aminoglycosides and carbapenem, which is associated with high morbidity and mortality in immunocompromised patients ( 2 , 3 ). Important to mention here that previous therapy with broad-range antibiotics, especially carbapenem has been deemed as a risk factor for S. maltophilia infection ( 4 , 5 ). The attributed mortality rates of S. maltophilia infections in pneumonia range between 25 and 75%, 26 and 28% in case of nosocomial bloodstream infections, and crude mortality rates of S. maltophilia bacteremia range from 21 to 69% ( 6 , 7 ).…”
Section: Introductionmentioning
confidence: 99%
“… S. maltophilia is an extremely challenging pathogen with very limited treatment options due to its prolific intrinsic resistome ( 26 , 27 ). Although SMX-TMP has traditionally been considered the drug of choice, there are no rigorous clinical data to support its use, and the optimal therapy remains unknown ( 13 ).…”
Section: Discussionmentioning
confidence: 99%
“…In the ubiquitous Gram-negative bacterium Stenotrophomonas maltophilia the main QS system described so far is mediated by the fatty acid signal cis -11-methyl-2-dodecenoic acid, also called DSF (for D iffusible S ignal F actor). S. maltophilia has emerged over the last decades as an opportunistic pathogen, causing nosocomial infections in the immunocompromised population and it is commonly isolated from the lungs of cystic fibrosis patients (6, 7). One of the main concerns about the members of this species is that they tend to be intrinsically resistant to multiple antibiotics, with specific isolates showing evidence of adaptive resistance (8, 9).…”
Section: Introductionmentioning
confidence: 99%